Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Top Posters at ACC Latin America 2025 Explore Myocardial Contraction Fraction, Vericiguat in HFrEF, Long COVIDAs hundreds of participants gathered to share and learn about the latest science from the Latin America region, the top three posters from ACC Latin America 2025 earned a spot to present at ACC.26 in New Orleans, LA.
- Intensive BP Control Provides Net Benefit Between Fewer CV and More Adverse EventsIntensive blood pressure (BP) control compared with standard BP control offers a net benefit between the decrease in cardiovascular events and increase in adverse events, including kidney-related events, according to a meta-analysis published Sept. 6 in The Lancet.
- Partial Heart Transplant Viable Option For Children With Congenital Valve DiseasePartial heart transplant provides a safe and effective valve replacement alterative with the capacity for valve growth in children with congenital heart disease, decreasing the need for reoperation, according to a small retrospective study published Aug. 27 in JAMA.
- Clopidogrel Superior to Aspirin For Prevention of MACCE in Patients With CADClopidogrel monotherapy is superior to aspirin monotherapy for prevention of major adverse cardiovascular or cerebrovascular events (MACCE) without increasing major bleeding risk and supports the use of clopidogrel over aspirin for secondary prevention in patients with coronary artery disease (CAD)...
- Research at ASE 2025: AI in Echocardiography, Baseline LV Health and Early TAVR, MoreResearch exploring the use of artificial intelligence (AI) in automating echocardiographic measurements, the impact of baseline left ventricular (LV) health on the benefit of early TAVR, and aortic regurgitation (AR) following use of percutaneous transaortic LV assist devices (pLAVD) was presented at ASE 2025 from Sept. 5-7 and simultaneously published in JACC and JACC: Cardiovascular […]